Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00389909
Other study ID # MRAP060309
Secondary ID
Status Completed
Phase Phase 4
First received October 17, 2006
Last updated February 23, 2017
Start date November 2006
Est. completion date November 2010

Study information

Verified date February 2017
Source Maternite Regionale Universitaire
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Doxapram is used to stimulate respiration. For a given dose, the fluctuations in concentrations observed in infants' blood may be wide, leading to a risk of lack of efficacy or of toxic effects. Two factors are linked to these fluctuations: age and gender. The aim of this study is to compare a dosage regimen based only on patient's weight, to another one using a dosing chart taking into account weight, age and gender.


Description:

Doxapram is a drug used to stimulate respiration in neonates prematurely born and failing to breathe. For a given dose, the fluctuations in concentrations of drug observed in infants' blood might be wide, leading to a risk of lack of efficacy of the treatment or of toxic effects. Two factors are linked to these fluctuations: age and gender. The aim of our study is to compare a dosage regimen based only on patient's weight, and another one using a dosing chart taking into account not only weight but also age and gender to prescribe the initial dose of doxapram. The final goal of this trial is to improve efficacy and tolerance of doxapram by minimizing the fluctuations in blood drug levels in premature neonates.


Recruitment information / eligibility

Status Completed
Enrollment 85
Est. completion date November 2010
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender All
Age group N/A to 3 Months
Eligibility Inclusion Criteria:

- Premature infants (<37 weeks gestation)

- More than 1 significant Apnea q 8h (> 20 sec or < 20 sec with bradycardia or desaturation)

- Already treated with caffeine

Exclusion Criteria:

- Intubation

- congenital malformation

- symptomatic apnea

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Doxapram
Dosing comparison between fixed scheduled and sex related dosage. Dosing related to weight only versus chart taking into account weight, age and gender.

Locations

Country Name City State
France Maternite Regionale Universitaire Nancy
France Hopital des Enfants Toulouse

Sponsors (1)

Lead Sponsor Collaborator
Jean Michel Hascoet

Country where clinical trial is conducted

France, 

References & Publications (1)

Barbé F, Hansen C, Badonnel Y, Legagneur H, Vert P, Boutroy MJ. Severe side effects and drug plasma concentrations in preterm infants treated with doxapram. Ther Drug Monit. 1999 Oct;21(5):547-52. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma level of Doxapram and its active metabolite (ketodoxapram) at 48 hours after the onset of treatment. 48 Hours
Secondary Efficacy (rate of significant apnea) 1 Week
See also
  Status Clinical Trial Phase
Completed NCT02580526 - Comparison of Mask Ventilation Techniques in Patients Requiring General Anesthesia N/A
Completed NCT02627001 - Nu-Mask Intraoral Airway Device Versus Conventional Bag Valve Mask Ventilation Crossover Trial Phase 4
Recruiting NCT01825473 - Study of Erythromycin in GER-Associated Apnea of the Newborn N/A
Completed NCT02103777 - High Versus Low Dose of Caffeine for Apnea of Prematurity Phase 3
Completed NCT00950287 - Detection of Neonatal Bradycardia N/A
Recruiting NCT00382876 - Identifying the Relative Change in Ventilation in Newborns With Placement in Car Bed or Car Seat N/A
Completed NCT00369759 - An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants N/A
Completed NCT04084535 - Effects of High Intensity Interval Training (HIIT) vs. Inspiratory Muscle Training on the Recovery After a Maximal Apnea. N/A
Recruiting NCT02968797 - Clinical Comparative Study to Validate Performance of SafeSed Prototype Monitoring Endoscopy Under Sedation
Completed NCT02554110 - Peripheral Nerve Stimulation to Reduce Hypoxic Events N/A
Not yet recruiting NCT04366414 - Breathing Protocol in Breath-hold Divers N/A
Completed NCT05124093 - The Effect of High-flow Nasal Oxygen Flow Rate on Gas Exchange During Apnoea N/A
Recruiting NCT01994785 - Use of Capnography in EGD and Colonoscopy With Moderate Sedation. N/A
Completed NCT01435486 - Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants N/A
Completed NCT01852929 - Sleep Apnea and Visual Perceptual Skill Learning N/A
Completed NCT00188968 - Randomized Trial of Nasal Continuous Positive Airway Pressure or Synchronized Nasal Ventilation in Premature Infants. Phase 3
Not yet recruiting NCT05396274 - High Flow Nasal Oxygen Therapy Undergoing Colonoscopy N/A
Completed NCT02800213 - Ventilation Using a Bag Valve Mask With Supplemental External Handle N/A
Completed NCT02375230 - MRSOPA-Drills to Improve Mask Ventilation in the Delivery Room N/A
Completed NCT02828280 - NuMask Versus Traditional Mask Ventilation During Routine Care N/A

External Links